NewAmsterdam Pharma (NAMS) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

NAMS NewAmsterdam Pharma

Watchlist

19.910
+0.510+2.63%

Close Feb 14 16:00 ET

20.500
+0.590+2.96%

Post 20:01 ET

2.08BMarket Cap-9.01P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Both Private Equity Firms Who Control a Good Portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Along With Institutions Must Be Dismayed After Last Week's 8.1% Decrease
Yahoo FinanceFeb 14 09:01 ET
NewAmsterdam Pharma to Present at Guggenheim's SMID Cap Biotech Conference
GlobeNewswireJan 29 08:00 ET
Express News | Form 144 | NewAmsterdam Pharma(NAMS.US) Insider Proposes to Sell 11.6 Million in Common Stocks
Moomoo NewsJan 27 17:15 ET
Express News | Form 144 | NewAmsterdam Pharma(NAMS.US) Insider Proposes to Sell 4.64 Million in Common Stocks
Moomoo NewsJan 27 16:55 ET
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $40
Moomoo NewsJan 24 07:33 ET · Ratings
Buy Recommendation for NewAmsterdam Pharma: Strong Potential of Obicetrapib Backed by Positive Phase 3 Trial Results and Market Positioning
TipRanksJan 17 01:08 ET

Comments

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15, 2024 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

103848509

Dec 10, 2024 07:21

$NewAmsterdam Pharma (NAMS.US)$ niceerr high fly prolly

Jaguar8

Nov 20, 2024 08:16

NEWS

$NewAmsterdam Pharma (NAMS.US)$
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg monotherapy at day 84 with statistical significa...

SteadyBoomBeepBeep

Nov 20, 2024 06:18

$NewAmsterdam Pharma (NAMS.US)$ on watch

NAMS NewAmsterdam Pharma

Trade Overview

Capital Trend

News

Comments

Trending Stocks